Literature DB >> 8519927

Excretion of a radiolabelled anticancer biodegradable polymeric implant from the rabbit brain.

A J Domb1, M Rock, C Perkin, G Yipchuck, B Broxup, J G Villemure.   

Abstract

The elimination of a clinically used anticancer biodegradable polymer implant (Gliadel) in the rabbit brain was studied. The implant is composed of N,N-bis(2-chloroethyl)-N-nitrosourea (BCNU) (1.6 wt%) dispersed in a copolyanhydride matrix of 1,3-bis(p-carboxyphenoxypropane) (CPP) and sebacic acid (SA) in a 20:80 molar ratio. Four groups of rabbits were implanted with wafers loaded with BCNU, one in a 14C-SA-labelled polymer, another in a 14C-CPP-labelled polymer and two groups with 14C-BCNU in a non-labelled polymer, one for BCNU disposition study and one for residual drug study. In the rabbits implanted with the 14C-SA-labelled polymer, approximately 10% of the radioactivity was found in the urine and 2% in the faeces, and about 10% remained in the device 7 d after implantation. In contrast, only 4% of the radioactivity of the 14C-CPP-labelled polymer was found in urine and faeces during this period. However, a drastic increase in the CPP excretion was found after 9 d, and at 21 d, 64% of the implanted 14C-CPP was found in the urine and faeces, and 29% was still in the recovered wafers. Approximately 50% of the BCNU in the wafers was released in 3 d, and over 95% was released after 6 d in the rabbit brain. This study demonstrates that BCNU-loaded polyanhydride is biodegradable and is excreted from the body primarily through the renal system. The water-soluble components SA and BCNU were rapidly excreted, while the insoluble CPP was gradually eliminated after a lag time of 9 d.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8519927     DOI: 10.1016/0142-9612(95)98902-q

Source DB:  PubMed          Journal:  Biomaterials        ISSN: 0142-9612            Impact factor:   12.479


  11 in total

1.  Biocompatibility of polysebacic anhydride microparticles with chondrocytes in engineered cartilage.

Authors:  Sathish Ponnurangam; Grace D O'Connell; Clark T Hung; Ponisseril Somasundaran
Journal:  Colloids Surf B Biointerfaces       Date:  2015-08-28       Impact factor: 5.268

2.  Ventricular opening and cerebrospinal fluid circulation accelerate the biodegradation process of carmustine wafers suggesting their immunomodulation potential in the human brain.

Authors:  Ichiyo Shibahara; Yukiko Shibahara; Hiroyuki Hagiwara; Takashi Watanabe; Yasushi Orihashi; Hajime Handa; Madoka Inukai; Takuichiro Hide; Yoshie Yasui; Toshihiro Kumabe
Journal:  J Neurooncol       Date:  2022-07-08       Impact factor: 4.506

3.  Phase II trial of Gliadel plus O6-benzylguanine in adults with recurrent glioblastoma multiforme.

Authors:  Jennifer A Quinn; Sara Xiaoyin Jiang; James Carter; David A Reardon; Annick Desjardins; James J Vredenburgh; Jeremy N Rich; Sridharan Gururangan; Allan H Friedman; Darell D Bigner; John H Sampson; Roger E McLendon; James E Herndon; Stevie Threatt; Henry S Friedman
Journal:  Clin Cancer Res       Date:  2009-02-01       Impact factor: 12.531

Review 4.  Pharmacokinetics of the carmustine implant.

Authors:  Alison B Fleming; W Mark Saltzman
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

5.  Interstitial chemotherapy with biodegradable BCNU (Gliadel) wafers in the treatment of malignant gliomas.

Authors:  Daniela A Bota; Annick Desjardins; Jennifer A Quinn; Mary L Affronti; Henry S Friedman
Journal:  Ther Clin Risk Manag       Date:  2007-10       Impact factor: 2.423

6.  Overexpression of Nrf2 attenuates Carmustine-induced cytotoxicity in U87MG human glioma cells.

Authors:  Sangeetha Sukumari-Ramesh; Niyathi Prasad; Cargill H Alleyne; John R Vender; Krishnan M Dhandapani
Journal:  BMC Cancer       Date:  2015-03-13       Impact factor: 4.430

Review 7.  Polifeprosan 20, 3.85% carmustine slow release wafer in malignant glioma: patient selection and perspectives on a low-burden therapy.

Authors:  Lawrence Kleinberg
Journal:  Patient Prefer Adherence       Date:  2016-11-24       Impact factor: 2.711

8.  Polifeprosan 20, 3.85% carmustine slow-release wafer in malignant glioma: evidence for role in era of standard adjuvant temozolomide.

Authors:  Lawrence Kleinberg
Journal:  Core Evid       Date:  2012-10-26

9.  Adjuvant chemotherapy for brain tumors delivered via a novel intra-cavity moldable polymer matrix.

Authors:  Cheryl V Rahman; Stuart J Smith; Paul S Morgan; Keith A Langmack; Phil A Clarke; Alison A Ritchie; Donald C Macarthur; Felicity R Rose; Kevin M Shakesheff; Richard G Grundy
Journal:  PLoS One       Date:  2013-10-14       Impact factor: 3.240

10.  Safety and efficacy of carmustine (BCNU) wafers for metastatic brain tumors.

Authors:  Chibawanye I Ene; John D Nerva; Ryan P Morton; Ariana S Barkley; Jason K Barber; Andrew L Ko; Daniel L Silbergeld
Journal:  Surg Neurol Int       Date:  2016-05-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.